Keen Vision Acquisition Corp. 8-K

What Happened

• Keen Vision Acquisition Corp. (the Parent) filed an 8-K disclosing that on February 26, 2026 it entered into a binding letter of intent (LOI) with Medera Inc. and Novoheart Group Limited (NVH). The LOI replaces the prior Merger Agreement dated September 3, 2024 (terminated by mutual release) and signals the parties’ intent to negotiate and execute a Replacement Merger Agreement by April 10, 2026.
• The contemplated transaction would merge NVH (a pre-clinical human disease modeling and drug-discovery business) into Parent, with Parent as the surviving company and listed on Nasdaq. The LOI sets NVH’s enterprise valuation at US$100,000,000 and requires the surviving company to have at least US$10,000,000 in available cash at closing (after transaction expenses and net of NVH liabilities).

Key Details

• LOI signed: February 26, 2026; Replacement Merger Agreement execution target: no later than April 10, 2026.
• NVH enterprise valuation: US$100,000,000. Minimum available cash at close: US$10,000,000.
• Closing-related cash expense caps: Parent up to US$700,000; NVH up to US$1,300,000.
• PIPE fundraising must close within nine months of the LOI (by ~November 26, 2026); the Replacement Merger Agreement will terminate if closing conditions are not met within nine months of the LOI. Sponsor promissory-note aggregate principal will be subject to a mutually agreed cap in the Replacement Merger Agreement.

Why It Matters

• This LOI restarts and re-frames the proposed business combination with Novoheart, sets a clear enterprise valuation (US$100M) and establishes minimum liquidity and expense caps that are material to deal feasibility.
• Key near-term milestones for investors are the April 10, 2026 target to execute a Replacement Merger Agreement and the nine-month deadlines for PIPE financing and satisfying closing conditions. Those milestones affect whether the deal proceeds, the amount of outside financing required, and potential impacts on public-shareholder liquidity and dilution.
• The filing is procedural but material: it replaces the prior merger contract, attaches the LOI and mutual release, and commits the parties to negotiate binding terms subject to board and shareholder approvals.